Common Contracts
15 similar Warrant Agreement contracts by Mateon Therapeutics Inc, Digital Power Corp, Oncotelic Therapeutics, Inc.
ONCOTELIC THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANTWarrant Agreement • July 13th, 2023 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Oncotelic Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share (the “Common Stock”) warrants to purchase 250,000 Common Stock (the “Offering”).
EDGEPOINT AI, INC. COMMON STOCK PURCHASE WARRANT ______________ (Date)Warrant Agreement • March 26th, 2021 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) to purchase the common stock (the “EdgePoint Common Stock”) of EdgePoint AI, Inc. (“EdgePoint”), a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below). The Company is a wholly-owned subsidiary of Mateon Therapeutics, Inc. “Mateon”). This Warrant is issued to the Holder as part of a unit purchased by the Holder from Mateon pursuant to which the Holder is also purchasing notes from Mateon convertible into shares of Mateon common stock (the “Mateon Common Stock”) and shares of EdgePoint Common Stock, and warrants, including this Warrant, to purchase shares of Edgemont Common Stock (the “Company Warrants”) and warrants to purchase shares of Mateon Common Stock, (the “Offering”).
MATEON THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT __________________ (Date)Warrant Agreement • March 26th, 2021 • Mateon Therapeutics Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Mateon Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share (the “Common Stock”), shares of the common stock of EdgePoint AI, Inc. (“EdgePoint”), a subsidiary of the Company wholly-owned by it, warrants, including this Warrant, to purchase shares of Common Stock and warrants to purchase EdgePoint’s common stock, (the “Offering”).
MATEON THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT AUGUST 7, 2020Warrant Agreement • August 13th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Mateon Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share (the “Common Stock”), shares of the common stock of EdgePoint AI, Inc. (“EdgePoint”), a subsidiary of the Company wholly-owned by it, warrants, including this Warrant, to purchase shares of Common Stock and warrants to purchase EdgePoint’s common stock, (the “Offering”).
EDGEPOINT AI, INC. COMMON STOCK PURCHASE WARRANT AUGUST 7, 2020Warrant Agreement • August 13th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) to purchase the common stock (the “EdgePoint Common Stock”) of EdgePoint AI, Inc. (“EdgePoint”), a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below). The Company is a wholly-owned subsidiary of Mateon Therapeutics, Inc. “Mateon”). This Warrant is issued to the Holder as part of a unit purchased by the Holder from Mateon pursuant to which the Holder is also purchasing notes from Mateon convertible into shares of Mateon common stock (the “Mateon Common Stock”) and shares of EdgePoint Common Stock, and warrants, including this Warrant, to purchase shares of Edgemont Common Stock (the “Company Warrants”) and warrants to purchase shares of Mateon Common Stock, (the “Offering”).
EDGEPOINT AI, INC. COMMON STOCK PURCHASE WARRANT JULY 23, 2020Warrant Agreement • July 29th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) to purchase the common stock (the “EdgePoint Common Stock”) of EdgePoint AI, Inc. (“EdgePoint”), a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below). The Company is a wholly-owned subsidiary of Mateon Therapeutics, Inc. “Mateon”). This Warrant is issued to the Holder as part of a unit purchased by the Holder from Mateon pursuant to which the Holder is also purchasing notes from Mateon convertible into shares of Mateon common stock (the “Mateon Common Stock”) and shares of EdgePoint Common Stock, and warrants, including this Warrant, to purchase shares of Edgemont Common Stock (the “Company Warrants”) and warrants to purchase shares of Mateon Common Stock, (the “Offering”).
MATEON THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT JULY 23, 2020Warrant Agreement • July 29th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Mateon Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share (the “Common Stock”), shares of the common stock of EdgePoint AI, Inc. (“EdgePoint”), a subsidiary of the Company wholly-owned by it, warrants, including this Warrant, to purchase shares of Common Stock and warrants to purchase EdgePoint’s common stock, (the “Offering”).
MATEON THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT February 14, 2020Warrant Agreement • June 29th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Mateon Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) by the Company in accordance with the terms of the Warrant Purchase Agreement between the Company and the Holder dated as of February __, 2020 pursuant to which Warrant the Holder ha the right to purchase shares of the Company’s Common Stock, $0.01 par value per share (the “Common Stock”) as set forth herein.
Warrant – No.: [●]Warrant Agreement • June 13th, 2018 • Mateon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”), AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT.
MATEON THERAPEUTICS, INC. COMMON STOCK PURCHASE A WARRANTWarrant Agreement • April 16th, 2018 • Mateon Therapeutics Inc • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE A WARRANT (this “Warrant”) of Mateon Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing shares of the Company’s Common Stock, $0.01 par value per share (the “Common Stock”), from the Company (the “Offering”).
Warrant – No.: [●]Warrant Agreement • April 16th, 2018 • Mateon Therapeutics Inc • Biological products, (no disgnostic substances)
THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT.
DIGITAL POWER CORPORATION COMMON STOCK PURCHASE WARRANT AUGUST 3, 2017Warrant Agreement • August 9th, 2017 • Digital Power Corp • Electronic components, nec • California
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Digital Power Corporation, a corporation duly organized and validly existing under the laws of California (the “Company”), is issued to the Holder (as defined below) in connection with a 12% Convertible Note (the “Note”). This Warrant is exercisable for up to an aggregate 666,666 shares of Common Stock, as defined below, subject to adjustment pursuant to the anti dilution provisions therein.
DIGITAL POWER CORPORATION REDEEMABLE COMMON STOCK PURCHASE WARRANT May __, 2017Warrant Agreement • May 31st, 2017 • Digital Power Corp • Electronic components, nec • New York
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Digital Power Corporation, a corporation duly organized and validly existing under the laws of California (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing shares of the Company’s Series C Preferred Stock from the Company (the “Offering”)..
DIGITAL POWER CORPORATION REDEEMABLE COMMON STOCK PURCHASE WARRANT OCTOBER 21, 2016Warrant Agreement • October 27th, 2016 • Digital Power Corp • Electronic components, nec • Nevada
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Digital Power Corporation, a corporation duly organized and validly existing under the laws of California (the “Company”), is issued to the Holder (as defined below) in connection with a 12% Secured Convertible Promissory Note (the “Note”) and another warrant (the “Warrant-CS1”) that the Holder is also simultaneously acquiring from the Company. This Warrant is exercisable for up to an aggregate 265,000 shares of Common Stock, as defined below, subject to adjustment pursuant to the anti dilution provisions therein.
DIGITAL POWER CORPORATION REDEEMABLE COMMON STOCK PURCHASE WARRANT OCTOBER 21, 2016Warrant Agreement • October 27th, 2016 • Digital Power Corp • Electronic components, nec • Nevada
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Digital Power Corporation, a corporation duly organized and validly existing under the laws of California (the “Company”), is issued to the Holder (as defined below) in connection with a 12% Secured Convertible Promissory Note (the “Note”) and another warrant (the “Warrant-CS2”) that the Holder is also simultaneously acquiring from the Company. This Warrant is exercisable for up to an aggregate 265,000 shares of Common Stock, as defined below, subject to adjustment pursuant to the anti dilution provisions therein.
